Who
we areAbout
Envetec
Envetec is an Irish company with a global vision to create clean change. Our mission is to enable all laboratories to move towards zero waste.
Envetec was founded in 2021 as a spin-out from Technopath Clinical Diagnostics, a leader in clinical diagnostics whose clients included global diagnostic companies and clinical laboratories. Envetec’s GENERATIONS™ – our clean technology – represents 10 years of investment in research and development combined with industry collaboration to deliver the best solution for the safe treatment of laboratory biohazardous materials and waste with the ability to achieve net zero carbon emissions.
One day all waste will be treated this way.
Envetec is disruptive. Our team comes from pharma, diagnostics, sport, business, technology, media, science and financial services.
With such widespread experience one would expect conflict but what has been achieved is a relentless curiosity. There has to be another way, a different way, a better way. We are not a waste processing company, we are a sustainable solution to create a circular economy, replacing current unsustainable practices. Our solution is the future, there is no reason to continue to cook, bury and burn valuable resources. There is a better way, the Envetec way.
Meet the Team
The people who
make it all happen
Envetec is building an experienced team with a tangible track record of success. At its core is a passion for excellence, a drive for innovation and a mission that will make a real difference. GENERATIONS is not just the name of our technology; it is a central tenet of our philosophy.
What can we learn from past generations, what can the younger generations teach us about the world they want to live in and how can we leave a beneficial legacy for future generations. Our Board has chaired or directed sector appropriate businesses in the past, our executives have delivered at the highest levels of performance and our team has the energy and curiosity to learn from the past to deliver for the future.
Leadership team
Malcolm Bell
Chair and Chief Executive Officer
Malcolm Bell serves as Chairman and Chief Executive Officer of Envetec Sustainable Technologies, Ireland's first cleantech company focused on breakthrough innovations to treat and repurpose laboratory waste materials on-site, significantly reducing dependency on landfills, incineration and autoclaving. Addressing the growing urgency to achieve a substantive path toward net-zero from the diagnostic, healthcare, and food and beverage industries, Malcolm established Envetec as a standalone business in 2021. Based on extensive R&D investment, the company is poised to transform the management of biohazardous, biomedical and regulated medical waste, introducing first-in-class environmentally friendly technologies.
In 2004, Malcolm co-founded Technopath Clinical Diagnostics, a global leader in developing and manufacturing innovative quality control (QC) solutions for clinical laboratories used in 125 countries. He served as CEO and oversaw the successful acquisition of the company to LGC in 2020.
Malcolm has a track record of creating significant value by advancing assets, intellectual property, technology, and product portfolios. In 2014, he spun out two companies from Technopath - ValitaCell Ltd and Oculer Ltd, respectively. Both spin-offs have allowed each company to commercialize disruptive technologies spanning drug discovery and development, food quality, food safety, and environmental monitoring applications.
Most recently, Malcolm consulted for New York's largest healthcare provider, Northwell Health, by being appointed President & CEO of Northwell Holdings and Ventures, the for-profit organization of the hospital network. Within 12 months, he created a five-year strategic roadmap to support critical funding initiatives, including evaluating the Health System's existing investment portfolio, investment companies, and joint ventures alongside introducing a new operating model and organizational structure.
Malcolm earned his undergraduate degree in molecular biology and his master's degree in biotechnology from the National University of Ireland.
Malcolm Bell
Chair and Chief Executive Officer
Malcolm Bell serves as Chairman and Chief Executive Officer of Envetec Sustainable Technologies.... read more
Malcolm Bell serves as Chairman and Chief Executive Officer of Envetec Sustainable Technologies, Ireland's first cleantech company focused on breakthrough innovations to treat and repurpose laboratory waste materials on-site, significantly reducing dependency on landfills, incineration and autoclaving. Addressing the growing urgency to achieve a substantive path toward net-zero from the diagnostic, healthcare, and food and beverage industries, Malcolm established Envetec as a standalone business in 2021. Based on extensive R&D investment, the company is poised to transform the management of biohazardous, biomedical and regulated medical waste, introducing first-in-class environmentally friendly technologies.
In 2004, Malcolm co-founded Technopath Clinical Diagnostics, a global leader in developing and manufacturing innovative quality control (QC) solutions for clinical laboratories used in 125 countries. He served as CEO and oversaw the successful acquisition of the company to LGC in 2020.
Malcolm has a track record of creating significant value by advancing assets, intellectual property, technology, and product portfolios. In 2014, he spun out two companies from Technopath - ValitaCell Ltd and Oculer Ltd, respectively. Both spin-offs have allowed each company to commercialize disruptive technologies spanning drug discovery and development, food quality, food safety, and environmental monitoring applications.
Most recently, Malcolm consulted for New York's largest healthcare provider, Northwell Health, by being appointed President & CEO of Northwell Holdings and Ventures, the for-profit organization of the hospital network. Within 12 months, he created a five-year strategic roadmap to support critical funding initiatives, including evaluating the Health System's existing investment portfolio, investment companies, and joint ventures alongside introducing a new operating model and organizational structure.
Malcolm earned his undergraduate degree in molecular biology and his master's degree in biotechnology from the National University of Ireland.
Peter Thornton
President and Chief Financial Officer
Peter Thornton is President, Chief Financial Officer and a founder of Envetec. Peter brings significant experience in corporate finance, business development and financial management in both public and private life science companies. Peter is a non-executive director of Avadel Pharmaceuticals plc, a NASDAQ listed biopharmaceutical company, and Oculer Limited, a company developing and commercialising proprietary rapid microbiology technology. Previously, he was CFO of Technopath Clinical Diagnostics (until its sale to LGC Group in 2021), a provider of quality control solutions to clinical laboratories worldwide.
Prior roles include SVP Corporate Development for Northwell Health, a leading US healthcare system; SVP Business Integration for Alkermes plc, a global biopharmaceuticals company; SVP Business and Product Development for Elan Corporation plc’s drug delivery division; President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical company; and CFO of Agenus Inc, a NASDAQ listed immuno-oncology biotechnology company.
Peter has served as a non-executive director of both public and private companies including Leon-Nanodrugs GmbH, Valitacell Limited, Merrion Pharmaceuticals plc, Cydex Pharmaceuticals Inc. and Antigenics Inc. Peter worked for the international public accounting firm of KPMG in Ireland and France and is a fellow of Chartered Accountants Ireland and a member of the Institute of Directors. He holds a Bachelor of Commerce degree from University College Cork, Ireland.
Peter Thornton
President and Chief Financial Officer
Peter Thornton is President, Chief Financial Officer and a founder of Envetec... read more
Peter Thornton is President, Chief Financial Officer and a founder of Envetec. Peter brings significant experience in corporate finance, business development and financial management in both public and private life science companies. Peter is a non-executive director of Avadel Pharmaceuticals plc, a NASDAQ listed biopharmaceutical company, and Oculer Limited, a company developing and commercialising proprietary rapid microbiology technology. Previously, he was CFO of Technopath Clinical Diagnostics (until its sale to LGC Group in 2021), a provider of quality control solutions to clinical laboratories worldwide.
Prior roles include SVP Corporate Development for Northwell Health, a leading US healthcare system; SVP Business Integration for Alkermes plc, a global biopharmaceuticals company; SVP Business and Product Development for Elan Corporation plc’s drug delivery division; President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical company; and CFO of Agenus Inc, a NASDAQ listed immuno-oncology biotechnology company.
Peter has served as a non-executive director of both public and private companies including Leon-Nanodrugs GmbH, Valitacell Limited, Merrion Pharmaceuticals plc, Cydex Pharmaceuticals Inc. and Antigenics Inc. Peter worked for the international public accounting firm of KPMG in Ireland and France and is a fellow of Chartered Accountants Ireland and a member of the Institute of Directors. He holds a Bachelor of Commerce degree from University College Cork, Ireland.
Keith Wood
Head of Corporate Development
Keith Wood is Head of Corporate Development at Envetec. He established W2 over 25 years ago, creating a group of businesses that support marketing & strategic planning, leadership development, client acquisition. W2 is a blend of his experience in international sport, broadcasting and business, built on an understanding of success and failure in high performing teams and individuals. Investor wise, Keith has followed his interests, from media to property, from sports science to rural regeneration, from healthy ageing to lifestyle businesses.
Keith captained the Irish Rugby Team 36 times, toured with the Lions twice, and is the inaugural winner of the World Player of the Year in 2001. Keith has worked extensively in journalism and media, writing for The Times, The Daily Telegraph, and Independent News as well as broadcasting for the BBC and Newstalk. He Chaired Spin South West and was Director of Communicorp Media until its sale in 2021 and is an Honorary Adjunct Professor for Sports Journalism at the University of Limerick.
He has been active in the public service and charity sectors advocating for closer links with key stakeholders and building relationships within and between different communities. Keith is an Honorary Fellow Of the Royal College of Surgeons for his Role as Chair of the Healthy Ireland Council and holds an Honorary Doctor of Science from UL for services to Sport and Community. In addition, he is a Patron of both the Special Olympics and the UNESCO Chair for Inclusive Physical Education, Sport, Recreation, and Fitness in Tralee IT.
Keith Wood
Head of Corporate Development
Keith Wood is Head of Corporate Development at Envetec... read more
Keith Wood is Head of Corporate Development at Envetec. He established W2 over 25 years ago, creating a group of businesses that support marketing & strategic planning, leadership development, client acquisition. W2 is a blend of his experience in international sport, broadcasting and business, built on an understanding of success and failure in high performing teams and individuals. Investor wise, Keith has followed his interests, from media to property, from sports science to rural regeneration, from healthy ageing to lifestyle businesses.
Keith captained the Irish Rugby Team 36 times, toured with the Lions twice, and is the inaugural winner of the World Player of the Year in 2001. Keith has worked extensively in journalism and media, writing for The Times, The Daily Telegraph, and Independent News as well as broadcasting for the BBC and Newstalk. He Chaired Spin South West and was Director of Communicorp Media until its sale in 2021 and is an Honorary Adjunct Professor for Sports Journalism at the University of Limerick.
He has been active in the public service and charity sectors advocating for closer links with key stakeholders and building relationships within and between different communities. Keith is an Honorary Fellow Of the Royal College of Surgeons for his Role as Chair of the Healthy Ireland Council and holds an Honorary Doctor of Science from UL for services to Sport and Community. In addition, he is a Patron of both the Special Olympics and the UNESCO Chair for Inclusive Physical Education, Sport, Recreation, and Fitness in Tralee IT.
Sunny Uberoi
Head of Communications and Public Affairs
Sunny is a seasoned communications strategist who has worked in senior roles across diverse sectors, including healthcare, financial services, technology, and consumer. Sunny has been advising CEOS of several startup companies specialising in gene therapy, type 2 diabetes, biohazardous waste, diagnostics, immuno-oncology, and organ transplantation from IPO readiness, advocacy, media to regulatory communications.
Sunny also served as the global head of communications for S&P Global Market Intelligence, Pfizer Consumer Healthcare, BMS, Agenus and Elan as well as holding various pharmaceutical industry marketing positions.
Sunny graduated with honors from Manchester Metropolitan University (Economics) and has a master’s in marketing from Manchester Business School.
Sunny Uberoi
Head of Communications and Public Affairs
Sunny is a seasoned communications strategist who has worked in senior roles across diverse sectors... read more
Sunny is a seasoned communications strategist who has worked in senior roles across diverse sectors, including healthcare, financial services, technology, and consumer. Sunny has been advising CEOS of several startup companies specialising in gene therapy, type 2 diabetes, biohazardous waste, diagnostics, immuno-oncology, and organ transplantation from IPO readiness, advocacy, media to regulatory communications.
Sunny also served as the global head of communications for S&P Global Market Intelligence, Pfizer Consumer Healthcare, BMS, Agenus and Elan as well as holding various pharmaceutical industry marketing positions.
Sunny graduated with honors from Manchester Metropolitan University (Economics) and has a master’s in marketing from Manchester Business School.
Michael Dowling
Non-Executive Director
Michael J. Dowling is president and chief executive officer of Northwell Health, which delivers world-class clinical care throughout the New York metropolitan area, pioneering research at the Feinstein Institutes for Medical Research and a visionary approach to medical education highlighted by the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies.
Northwell Health is the largest integrated health care system in New York State with a total workforce of more than 70,000 employees — the state’s largest private employer. With 23 hospitals, 6,675 hospital and long-term care beds, more than 750 outpatient physician practices and a full complement of long-term care services, Northwell is one of the nation’s largest health systems, with $12 billion in annual revenue.
Prior to becoming president and CEO in 2002, Mr. Dowling was the health system’s executive vice president and chief operating officer. Before joining Northwell Health in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield.
Mr. Dowling served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services.
Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County.
Michael Dowling
Non-Executive Director
Michael J. Dowling is president and chief executive officer of Northwell Health, which delivers world-class clinical care throughout the New York metropolitan area.... read more
Michael J. Dowling is president and chief executive officer of Northwell Health, which delivers world-class clinical care throughout the New York metropolitan area, pioneering research at the Feinstein Institutes for Medical Research and a visionary approach to medical education highlighted by the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies.
Northwell Health is the largest integrated health care system in New York State with a total workforce of more than 70,000 employees — the state’s largest private employer. With 23 hospitals, 6,675 hospital and long-term care beds, more than 750 outpatient physician practices and a full complement of long-term care services, Northwell is one of the nation’s largest health systems, with $12 billion in annual revenue.
Prior to becoming president and CEO in 2002, Mr. Dowling was the health system’s executive vice president and chief operating officer. Before joining Northwell Health in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield.
Mr. Dowling served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services.
Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County.
Enda Kenny
Non-Executive Director
Enda Kenny was elected to Dáil Éireann, the Irish National Parliament at 24 years of age in 1975. He was re-elected in 12 subsequent General Elections until his retirement as Taoiseach in 2017.
He served as Minister for Education and Tourism and Trade and became Leader of Fine Gael in 2002. He led the Party for 15 years, the longest period of any Fine Gael Leader.
Enda became Taoiseach in March 2011 and again in May 2016, the first Fine Gael Leader to be re-elected as Taoiseach in successive elections.
Under his leadership, Ireland became the fastest growing EU country for 4 successive years; unemployment reduced from 15.2% to less than 5%; and interest rates on Irish borrowing fell from 15% to zero, restoring the country’s credit rating.
Mr Kenny was conferred with an Honorary Doctorate in Law by National University of Ireland, Galway (NUIG).
Enda Kenny
Non-Executive Director
Enda Kenny was elected to Dáil Éireann, the Irish National Parliament at 24 years of age in 1975. He was re-elected in 12 subsequent General Elections until his retirement as Taoiseach in 2017.... read more
Enda Kenny was elected to Dáil Éireann, the Irish National Parliament at 24 years of age in 1975. He was re-elected in 12 subsequent General Elections until his retirement as Taoiseach in 2017.
He served as Minister for Education and Tourism and Trade and became Leader of Fine Gael in 2002. He led the Party for 15 years, the longest period of any Fine Gael Leader.
Enda became Taoiseach in March 2011 and again in May 2016, the first Fine Gael Leader to be re-elected as Taoiseach in successive elections.
Under his leadership, Ireland became the fastest growing EU country for 4 successive years; unemployment reduced from 15.2% to less than 5%; and interest rates on Irish borrowing fell from 15% to zero, restoring the country’s credit rating.
Mr Kenny was conferred with an Honorary Doctorate in Law by National University of Ireland, Galway (NUIG).
Eva Pisa PhD; MBA
Non-Executive Director
Eva Pisa is a leader in health diagnostics and biotechnology and has extensive leadership experience from start-up to corporate companies. She earned her PhD in immunology at the Karolinska Institute in Stockholm Sweden, and she holds an MBA from Heriot-Watt University, Edinburgh, Scotland.
Eva Pisa was the CEO of a Swedish molecular diagnostic start-up from 2001 and 2007 that subsequently was acquired by Cepheid now a part of Danaher. The company was specialised in infectious disease affecting immune compromised patients. Eva Pisa subsequently joined Roche Diagnostics International where she held responsibilities including Life Cycle Leader Microbiology and Global Head of Product Development for Roche Molecular Diagnostics (2007-2016). During her tenure the highly successful Roche cobas 6800 and 8800 System was developed and launched. As an SVP at Roche Centralized and PoC Solutions (2016-2020) she was responsible for the Clinical Chemistry, Endocrinology and Custom Biotech (B2B business) and retired from Roche Diagnostics International in 2020.
Eva Pisa continues to support and consult with diagnostic and life science companies through piMed Consulting AG, and she is a bord member of HSE AG, Hombrechtikon, Switzerland.
Eva Pisa PhD; MBA
Non-Executive Director
Eva Pisa was the CEO of a Swedish molecular diagnostic start-up from 2001 and 2007 that subsequently was acquired by Cepheid now a part of Danaher. ... read more
Eva Pisa is a leader in health diagnostics and biotechnology and has extensive leadership experience from start-up to corporate companies. She earned her PhD in immunology at the Karolinska Institute in Stockholm Sweden, and she holds an MBA from Heriot-Watt University, Edinburgh, Scotland.
Eva Pisa was the CEO of a Swedish molecular diagnostic start-up from 2001 and 2007 that subsequently was acquired by Cepheid now a part of Danaher. The company was specialised in infectious disease affecting immune compromised patients. Eva Pisa subsequently joined Roche Diagnostics International where she held responsibilities including Life Cycle Leader Microbiology and Global Head of Product Development for Roche Molecular Diagnostics (2007-2016). During her tenure the highly successful Roche cobas 6800 and 8800 System was developed and launched. As an SVP at Roche Centralized and PoC Solutions (2016-2020) she was responsible for the Clinical Chemistry, Endocrinology and Custom Biotech (B2B business) and retired from Roche Diagnostics International in 2020.
Eva Pisa continues to support and consult with diagnostic and life science companies through piMed Consulting AG, and she is a bord member of HSE AG, Hombrechtikon, Switzerland.
Imogen Joss
Non-Executive Director
Imogen spent her executive career in the fintech arena as Commercial Director of the London Stock Exchange and latterly President of two divisions of S&P Global. She brings global experience to the boards that she serves plus a strong commercial, client and talent-focused agenda while specialising in Remuneration Committee work on both listed and non-listed boards.
She currently serves on the boards of five organisations across advisory services, fintech and cleantech including as Chair of Grant Thornton UK llp and SID at Fintel plc.
As well as mentoring a number of CEOs and senior leaders, as Chair of Trustees of a charity focused on the alleviation of rural child poverty in the UK, Imogen and her team support those at the sharp end of delivering education, health care and social support.
Imogen Joss
Non-Executive Director
Imogen spent her executive career in the fintech arena as Commercial Director of the London Stock Exchange and latterly President of two divisions of S&P Global. ... read more
Imogen spent her executive career in the fintech arena as Commercial Director of the London Stock Exchange and latterly President of two divisions of S&P Global. She brings global experience to the boards that she serves plus a strong commercial, client and talent-focused agenda while specialising in Remuneration Committee work on both listed and non-listed boards.
She currently serves on the boards of five organisations across advisory services, fintech and cleantech including as Chair of Grant Thornton UK llp and SID at Fintel plc.
As well as mentoring a number of CEOs and senior leaders, as Chair of Trustees of a charity focused on the alleviation of rural child poverty in the UK, Imogen and her team support those at the sharp end of delivering education, health care and social support.
James Connelly
Non-Executive Director
James is a sustainability executive with a significant track record of growing organizations that have transformed industries in multiple sectors, including manufacturing, real estate, tech, and life science.
Over his career, he has consulted with and developed sustainability programs for some of the world's largest companies and institutions. An internationally recognised corporate sustainability expert, James has deep knowledge of ESG reporting and strategy.
James was selected as a Greenbiz 30 under 30 sustainable business leader in 2017 and a Net Zero Energy Trailblazer in 2019 and is passionate about rapidly catalyzing a global transition to Net-Zero Carbon.
James Connelly
Non-Executive Director
James is a sustainability executive with a significant track record of growing organizations that have transformed industries in multiple sectors, including manufacturing, real estate, tech, and life science. ... read more
James is a sustainability executive with a significant track record of growing organizations that have transformed industries in multiple sectors, including manufacturing, real estate, tech, and life science.
Over his career, he has consulted with and developed sustainability programs for some of the world's largest companies and institutions. An internationally recognised corporate sustainability expert, James has deep knowledge of ESG reporting and strategy.
James was selected as a Greenbiz 30 under 30 sustainable business leader in 2017 and a Net Zero Energy Trailblazer in 2019 and is passionate about rapidly catalyzing a global transition to Net-Zero Carbon.
I am Malcolm Bell the founder of Envetec. I have been very fortunate to have built a career in sectors that have a major positive impact on people’s health.
I built the Technopath group of companies from humble beginnings as a distribution company serving the UK and Irish markets, into five standalone businesses serving the global pharmaceutical/med tech, diagnostic and food & beverage industries.
Envetec grew out of that experience, eventually becoming one of the fastest growing and most exciting parts of the business, by focusing on finding new, cleaner ways to treat biohazardous laboratory waste. Now that it has become a standalone business, I could not be more excited about our bold mission to create clean change.
The advances in healthcare have made enormous tangible benefits to people’s lives – we are living longer with a much-improved quality of life as a direct result.
Over time I have witnessed first-hand that while the advances in healthcare have positively impacted humanity, the Everest of biohazardous laboratory waste generated by healthcare, predominantly plastic waste, continues to grow.
Simply put, while the developers and manufacturers of all these beneficial products and technologies have consistently innovated, no one has put either the effort or investment into dealing with the very significant negative environmental issues these products cause after use.
The fact is, the companies that have innovated and positively impacted humanity have done so by specialising. These biotech and medical device pioneers cannot also be expected to find better ways to treat the products they have developed. And that’s why Envetec was born.
For the past ten years I have invested in R&D to tackle this problem by evaluating existing technologies, challenging current methodologies and ultimately deciding to face the challenge head on and develop technology to eradicate the use of road haulage, autoclaves, landfill and incineration of biohazardous laboratory materials and waste. Our aim is to create a circular economy for biohazardous laboratory waste. This has become my sole focus and ambition.
This was far too big a proposition for me to tackle alone, so for the last few years I have built a team around me to help make these ambitions a reality.
Our Executive team is an experienced group of high performers and leaders with strong individual track records. We have delivered in pharmaceuticals, med-tech, diagnostics, finance, sport, media, psychology and PR and we are all looking to make a difference.
Our Management team is younger, driven by purpose and full of energy and ambition while our Board is comprised of country leaders, CEOs of not-for-profit entities, SVP’s of publicly quoted multinationals and the head of one of the largest healthcare systems in America.
In one fell swoop we have built a full team of three generations of positive energy, purpose, experience, track records and most importantly credibility.
We don’t believe we can change the world, but we do believe we can change one dirty part of it. We want to have an impact which will benefit future generations and as un-glamorous as it may sound, we have chosen turning biohazardous laboratory waste into something useful as our sphere of influence.
We are Envetec Sustainable Technologies, a clean technology company, solving problems you may not even know about yet and we will positively contribute to addressing the Climate Crisis we all face.